If you look at Bell's valuation and remove the probability ratios (assuming P3 success and FDA approval) they have Neuren valued at $800m on Trofinetide for Retts and Fragile X alone. Success of the Trofinetide molecule then adds weight to the potential of NNZ-2591 the value of which needs to be added to the $800m plus the multitude of other potential applications for either drug.
I my view if it isn't $1B minimum then we haven't achieved full value and the board should continue down the P3 path until we do. I would be disappointed if the sold out early for less than this. I think the shareholders have shown they are in for the long haul and we should run the course to unlock full potential.
- Forums
- ASX - By Stock
- NEU
- Neuren - Cracking the $200m m/cap again.
Neuren - Cracking the $200m m/cap again., page-47
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.94 |
Change
0.330(2.42%) |
Mkt cap ! $1.763B |
Open | High | Low | Value | Volume |
$13.60 | $14.00 | $13.51 | $1.916M | 138.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 583 | $13.93 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.94 | 40 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 269 | 13.960 |
3 | 307 | 13.950 |
8 | 517 | 13.940 |
10 | 1372 | 13.930 |
7 | 710 | 13.920 |
Price($) | Vol. | No. |
---|---|---|
13.980 | 783 | 3 |
13.990 | 2061 | 10 |
14.000 | 7454 | 11 |
14.010 | 499 | 3 |
14.020 | 742 | 4 |
Last trade - 13.17pm 13/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |